Table.
Characteristics of study subjects.
| Characteristic | Healthy n=20 |
Asthma n=26 |
SCD n=20 |
SLE n=20 |
SOT n=24 |
|---|---|---|---|---|---|
|
| |||||
| Age* | |||||
| Mean ± SD (years) | 7.9 ± 6.4 | 9.8 ± 5.5 | 12.1 ± 5.8 | 12.7 ± 3.4 | 13.5 ± 5.9 |
| Number (n) < 3 yrs | 7 | 1 | 2 | 0 | 1 |
|
| |||||
| Ethnicity | |||||
| Asian/Indian | 1 | 5 | 0 | 3 | 4 |
| Black | 5 | 11 | 15 | 9 | 7 |
| Hispanic | 11 | 9 | 5 | 7 | 8 |
| White | 3 | 1 | 0 | 1 | 5 |
|
| |||||
| Sex | |||||
| Female | 10 | 17 | 4 | 16 | 8 |
| Male | 10 | 9 | 16 | 4 | 16 |
|
| |||||
| Time to follow up | |||||
| Mean ± SD (days) | 44.6 ± 2.3 | 42.2 ± 9.8 | 41.3 ± 2.8 | 47.1 ± 3.8 | 53.2 ± 4.4 |
|
| |||||
| Tacrolimus (n) | 24 | ||||
| Mean level ± SD, ng/ml | 5.36 ± 2.23 | ||||
|
| |||||
| Daily prednisone (n) | 3 | 16 | 21 | ||
| Median mg/kg/day (range)** | 0.2(0.09–2.2) | 0.3(0.1–0.9) | 0.1(0.03–0.8) | ||
|
| |||||
| Hydroxyurea (n) | 14 | ||||
| Mean mg/kd/day ± SD | 23.5 ± 6.6 | ||||
|
| |||||
| Mycophenolate mofetil (n)*** | 7 | 18 | |||
Immunosuppressant medications reflect doses and levels at the time of enrollment.
*
Healthy subjects were significantly younger than all groups, except children with asthma.
**
Subjects with SLE received significantly higher doses of prednisone compared with recipients of SOT(p<0.001)
***
Recipients of SOT were more likely to receive mycophenolate mofetil relative to subjects with SLE (p=0.02).
One recipient of SOT received azathioprine in addition to tacrolimus and prednisone.